09:57 AM EDT, 10/24/2024 (MT Newswires) -- GSK (GSK) reported Thursday that preliminary data from a phase 3 study of its respiratory syncytial virus vaccine Arexvy demonstrated its potential to help protect a larger group of adults at risk from getting RSV.

The British pharmaceutical company said the trial, which involved patients between the ages of 18 and 49, could expand the approved age range for the vaccine. The company said Arexvy is currently approved for people aged 60 and older in more than 50 countries, and for people aged 50 to 59 at increased risk in the US and Europe.

Price: 38.08, Change: +0.10, Percent Change: +0.26